Navigation Links
VIVUS to Present at the BioCentury NewsMakers Conference
Date:10/14/2011

MOUNTAIN VIEW, Calif., Oct. 14, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that Timothy Morris, chief financial officer, will present an overview of the company at the 2011 BioCentury NewsMakers in the Biotech Industry Conference.

The VIVUS presentation will take place at the Millennium Broadway Hotel in New York, NY on Friday, October 21, 2011 at 10:00 a.m. ET.  A live webcast and 30-day archive of the presentation will be available at http://ir.vivus.com.

About VIVUS VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company's lead investigational product in clinical development, QNEXA®, has completed phase 3 clinical trials for the treatment of obesity and is currently being considered for approval by US and EU regulators. VIVUS received a Complete Response Letter, or CRL, to the initial QNEXA NDA on October 28, 2010. QNEXA is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS has submitted an NDA for avanafil, a PDE5 inhibitor being studied for the treatment of erectile dysfunction. For more information about the company, please visit www.vivus.com.CONTACT:   VIVUS, Inc.Investor Relations:The Trout GroupTimothy E. MorrisBrian KorbChief Financial Officerbkorb@troutgroup.com 650-934-5200646-378-2923
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. VIVUS to Participate in Three Investor Conferences in September
2. VIVUS Announces Positive Phase 3 Results of Avanafil in Radical Prostatectomy Patients
3. VIVUS Reports First Quarter 2011 Financial Results
4. VIVUS to Present at Four Upcoming Investor Conferences in May
5. VIVUS to Present at the 10th Annual Needham Healthcare Conference
6. Data on VIVUS QNEXA to be Presented in Six Posters at The Obesity Societys Annual Meeting
7. VIVUS to Present at Four Upcoming Investor Conferences
8. VIVUS to Present at Two Upcoming Investor Conferences
9. VIVUS Reports Third Quarter 2009 Highlights and Financial Results
10. VIVUS Announces Positive Results From Two Phase 3 Studies; Obese Patients on Qnexa Achieve Average Weight Loss up to 14.7% and Significant Improvements in Co-Morbidities
11. VIVUS to Present at Four Upcoming Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Research and ... addition of Jain PharmaBiotech,s new report ... to their offering. The scope ... in situ hybridization (FISH), comparative genomic hybridization ... application of nanobiotechnology, microarrays, real-time polymerase chain ...
(Date:9/2/2015)... ... September 02, 2015 , ... Drug companies increasingly are adopting ... Research reveals in its new report that the U.S. will generate the greatest ... generates the most market demand. , BCC Research examines plant-derived drugs in ...
(Date:9/2/2015)... 2015 Australian prostate cancer technology company Minomic ... prize recognising ,outstanding, science that uses its patented antibody. ... a novel prostate cancer diagnostic test known as MiCheck® ... taking out the peer-reviewed Australian Museum Eureka Science Prize ... This prize is awarded for ground breaking research ...
(Date:9/2/2015)... , Sept. 2, 2015 Veracyte, Inc. ... H. Anderson , president and chief executive officer, will ... Wednesday, September 16, 2015 at 10:30 a.m. ET in ... The live audio webcast and subsequent replay may ... webcast will be available shortly after conclusion of the ...
Breaking Biology Technology:Global Cytogenetics Technologies Study 2015-2025 - Latest Markets and Companies Analysis 2Global Cytogenetics Technologies Study 2015-2025 - Latest Markets and Companies Analysis 3Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 2Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 3Prostate Cancer Company Minomic Wins Prestigious Eureka Science Prize 2Prostate Cancer Company Minomic Wins Prestigious Eureka Science Prize 3Veracyte to Present at Morgan Stanley Global Healthcare Conference 2
... October 5 , - A New Miniaturized PCR ... Price of QuanTyper(TM) Without Loss of Performance, - ... AlphaHelix (Ticker: ALPH) has in a very ... for lower,instrument prices. This was made possible through know-how obtained during,the ...
... Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today reported ... bavituximab in combination with carboplatin and paclitaxel in patients ... reported from the initial cohort of 21 patients in ... patients with locally advanced or metastatic NSCLC achieved an ...
... ... Global packaging specialist,Sepha, says the increased pressure to reduce costs and ... and blister-scanning technologies. While blisterpacks offer pharmaceutical companies a simple ... often makes it difficult to either test for leaks or recover ...
Cached Biology Technology:AlphaHelix Presents AmpXpress(TM) at the BIOTECHNICA Show 2Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial 2Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial 3Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial 4Environmental & Economic Factors Drives Global Demand for Pharmaceutical leak Testing and Deblistering 2Environmental & Economic Factors Drives Global Demand for Pharmaceutical leak Testing and Deblistering 3
(Date:8/12/2015)... 12, 2015 As the digital ... innovation and advanced biometrics technology is accelerating beyond expectations.  ... rely on using their credit cards, the digital currency, ... for payment services led by companies in the space ... Google, Inc. (NASDAQ: GOOG ), Apple Inc. (NASDAQ: ...
(Date:8/12/2015)... SAN JOSE, Calif. , Aug. 12, 2015 ... leading developer of human interface solutions, today announced ... the recently announced Match-in-Sensor solution, have officially been ... (FIDO) Alliance. As part of the certification, Synaptics, ... the FIDO 1.0 Universal Authentication Framework (UAF) standard ...
(Date:8/10/2015)... Germany , August 10, 2015 ... in Eye Tracking Technology for more than two decades, ... Platform for integration into all consumer display formats. The ... seamless integration of eye tracking into consumer tablets, laptops, ... reality smart glasses. Omnivision,s leading sensor technology contributes to ...
Breaking Biology News(10 mins):Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3
... LyondellBasell announced the following schedule and contact information for a teleconference on financial results through the ... , Monday, August 16, 2010 , ... Doug Pike, Vice President, Investor Relations , ... 800-369-1176 , London: 0800-279-9630 , ...
... Georgia Institute of Technology are using funding from the ... as ARPA-E to pursue two different, but related, ... of coal-burning power plants. Power plants ... the United States each year. The researchers will ...
... URBANA A dog,s indiscriminate taste is not always ... gastrointestinal infections and consequent ailments such as diarrhea and ... gastrointestinal diseases such as inflammatory bowel diseases that are ... by intestinal bacteria. Researchers at the University ...
Cached Biology News:Teleconference Alert: LyondellBasell Reviews Second Quarter 2010 Financial Results 2ARPA-E funding supports research on carbon dioxide removal from flue gases 2ARPA-E funding supports research on carbon dioxide removal from flue gases 3ARPA-E funding supports research on carbon dioxide removal from flue gases 4Illinois researchers use pyrosequencing to study canine intestinal bacteria 2
... Simultaneously perform 96 assays on four slides. ... microarray slides with 96 (6mm x 7mm) ... gene expression, or screening analysis studies. Unlike ... fit gasket, eliminating the presence of contaminating ...
... of Use : GeneTraffic is built to ... biological research. GeneTraffic provides visual and computational ... data prior to analysis. , Data ... projects using the MIAME (Minimum Information About ...
... siTrio siRNA --- a cocktail of 3 ... of interestis our most popular product. The ... 75% knockdown of your target gene when ... for transfection and confirmation of optimal transfection ...
... kit #27295 has improved stability and convenience from ... not only has overcome this problem but also ... have changed the formulation of HRP conjugated antibody ... By this change, the stability of the conjugate ...
Biology Products: